Fluzac Capsule 20 mg (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is 20 mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20–80 mg per day were administered. If no improvement is observed, a dose increase may be considered after several weeks. Doses exceeding 20 mg per day should be administered twice daily (morning and noon), and the maximum dose of 80 mg per day should not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks of treatment or longer. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this medicine, but psychopharmacologists recognize that acute signs of depression require medication treatment for several months or longer. It is not known whether the dose of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain remission. 2. Bulimia nervosa Administer 60 mg of this medicine per day. The daily dose should not exceed 80 mg. Measure electrolyte levels before starting treatment. 3. Obsessive-compulsive disorder Administer 20–60 mg of this medicine per day. The daily dose should not exceed 80 mg. 4. Premenstrual dysphoric disorder Administer 20 mg of this medicine per day. After 6 months of treatment, reassess whether continued treatment is necessary. Patients with renal and/or hepatic impairment, patients receiving multiple medications, older patients, and patients with comorbid diseases: Administer a lower dose or reduce the frequency of administration. Adjust the dose as appropriate according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this medicine, allow an interval of at least 14 days. Conversely, when starting an MAO inhibitor to treat a psychiatric disorder, at least 5 weeks must have elapsed after discontinuing this medicine. Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization and other interventional procedures, consider administration. It may be necessary to urgently administer linezolid or intravenous methylene blue to a patient already receiving this medicine. If there is no alternative to linezolid or intravenous methylene blue and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, discontinue this medicine immediately and administer linezolid or intravenous methylene blue. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be restarted 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by a non-intravenous route (oral tablets or local injection) or intravenous administration of this medicine at a dose of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is primarily an antidepressant used for treating psychiatric conditions such as depression. It may increase the risk of suicidal impulses or behaviors, especially in young adults aged 18 to 24. Therefore, when administering to patients within this age group, the physician should carefully evaluate the risks and benefits. This medication should not be used in patients with a history of allergic reactions or severe renal impairment, or those taking MAO inhibitors, which are a specific class of medications. Particular caution is needed for patients with a history of seizures or at risk for suicide, as well as those exhibiting manic or hypomanic symptoms, and patients with heart disease or impaired liver and kidney function should be given this medication carefully. Patients with diabetes may experience changes in blood sugar control while taking this medication, so regular blood glucose monitoring is advisable. Additionally, this medication can cause pupil dilation; thus, patients with elevated intraocular pressure or at risk for glaucoma should be cautious. Common side effects include headache, nausea, insomnia, fatigue, diarrhea, while severe allergic reactions, bleeding, and cardiac arrhythmias can occur rarely. During the course of taking this medication, careful monitoring for changes in mental status such as suicidal impulses, aggression, anxiety, and mania is necessary, and family or caregivers should watch the patient closely and consult a doctor immediately if any unusual signs arise. During pregnancy, this medication should only be used when absolutely necessary due to the potential risks to the fetus, and in nursing mothers, caution is required as the drug can be transmitted through breast milk. Abrupt discontinuation of this medication may result in withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so dosage should be decreased gradually under medical supervision. This medication may interact with other drugs, and patients should consult their doctor or pharmacist if they are currently taking, or plan to take, any other medications. Caution is advised when driving or operating machinery, and alcohol consumption is not recommended. The safety and efficacy of this medication in children and adolescents have not been established; thus, use should be avoided if possible. In the elderly, this medication should also be used cautiously, and in cases of overdose, the patient should seek medical attention immediately for appropriate treatment. This medication should be stored out of the reach of children and should not be transferred to another container.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylaxis, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, irritability, restlessness, tension, decreased libido, sleep disturbance, abnormal dreams, depersonalization, elevated mood, happy mood, thought disorder, sexual dysfunction, bruxism, hypomania, mania, hallucinations, agitation, panic attacks, suicidal thoughts and behaviors, confusion, attention deficit, dizziness, taste disturbances, hypersomnia, drowsiness, trembling, psychomotor agitation, movement disorders, ataxia, balance disorders, myoclonus, seizures, akathisia, Bucco glossal syndrome, serotonin syndrome, memory impairment, blurred vision, mydriasis, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, pulmonary-related events, epistaxis, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, hyperhidrosis, alopecia, increased tendency for bruising, diaphoresis, angioedema, petechiae, phototoxic reactions, purpura, erythema multiforme, arthralgia, myopathy, myalgia, frequency of urination, dysuria, urinary retention, micturition disorders, gynecological bleeding, erectile dysfunction, ejaculation disorders, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, malaise, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, suicidal ideation, suicidal behavior, fractures, withdrawal symptoms, dizziness, sensory disturbances, sleep disorders, asthenia, agitation, anxiety, trembling, headache, aplastic anemia, atrial fibrillation, cataract, cerebrovascular accident, cholestatic jaundice, hyperkinetic movement disorder, eosinophilic pneumonia, epithelial necrosis, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, worsening movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to be kept at room temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's efficacy and allow for safe use.

Appearance

A hard capsule with a green upper part and a light yellow lower part filled with a light gray powder.

Package unit

30 capsules/bottle, 500 capsules/bottle